These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 33600237)

  • 1. Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys.
    Fuwa M; Shimazaki A; Odani-Kawabata N; Kirihara T; Taniguchi T; Iwamura R; Yoneda K; Kato M; Morishima K; Shams NK
    J Ocul Pharmacol Ther; 2021 May; 37(4):223-229. PubMed ID: 33600237
    [No Abstract]   [Full Text] [Related]  

  • 2. Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug.
    Sharif NA
    Curr Opin Pharmacol; 2024 Feb; 74():102426. PubMed ID: 38168596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys.
    Fuwa M; Toris CB; Fan S; Taniguchi T; Ichikawa M; Odani-Kawabata N; Iwamura R; Yoneda K; Matsugi T; Shams NK; Zhang JZ
    J Ocul Pharmacol Ther; 2018 Sep; 34(7):531-537. PubMed ID: 29989843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent.
    Kirihara T; Taniguchi T; Yamamura K; Iwamura R; Yoneda K; Odani-Kawabata N; Shimazaki A; Matsugi T; Shams N; Zhang JZ
    Invest Ophthalmol Vis Sci; 2018 Jan; 59(1):145-153. PubMed ID: 29332128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study.
    Aihara M; Ropo A; Lu F; Kawata H; Iwata A; Odani-Kawabata N; Shams N
    Jpn J Ophthalmol; 2020 Jul; 64(4):398-406. PubMed ID: 32572719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study).
    Aihara M; Lu F; Kawata H; Tanaka Y; Yamamura K; Odani-Kawabata N; Shams NK
    J Ocul Pharmacol Ther; 2019 Dec; 35(10):542-550. PubMed ID: 31674861
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension.
    Aihara M; Lu F; Kawata H; Iwata A; Liu K; Odani-Kawabata N; Shams NK
    J Glaucoma; 2019 May; 28(5):375-385. PubMed ID: 30839416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan.
    Miki A; Miyamoto E; Ishida N; Shii D; Hori K;
    Adv Ther; 2022 May; 39(5):2085-2095. PubMed ID: 35287233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl.
    Iwamura R; Tanaka M; Okanari E; Kirihara T; Odani-Kawabata N; Shams N; Yoneda K
    J Med Chem; 2018 Aug; 61(15):6869-6891. PubMed ID: 29995405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study.
    Aihara M; Lu F; Kawata H; Iwata A; Odani-Kawabata N; Shams NK
    Am J Ophthalmol; 2020 Dec; 220():53-63. PubMed ID: 32533949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3).
    Bacharach J; Brubaker JW; Evans DG; Lu F; Odani-Kawabata N; Yamabe T; Wirta DL
    Am J Ophthalmol; 2024 Jul; 263():23-34. PubMed ID: 38395329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study.
    Aihara M; Lu F; Kawata H; Iwata A; Odani-Kawabata N
    Jpn J Ophthalmol; 2021 Nov; 65(6):810-819. PubMed ID: 34495425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Patient Tolerability of Omidenepag Isopropyl in the Treatment of Glaucoma and Ocular Hypertension.
    Matsuo M; Matsuoka Y; Tanito M
    Clin Ophthalmol; 2022; 16():1261-1279. PubMed ID: 35510270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma.
    Prasanna G; Carreiro S; Anderson S; Gukasyan H; Sartnurak S; Younis H; Gale D; Xiang C; Wells P; Dinh D; Almaden C; Fortner J; Toris C; Niesman M; Lafontaine J; Krauss A
    Exp Eye Res; 2011 Sep; 93(3):256-64. PubMed ID: 21376717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice.
    Esaki Y; Katsuta O; Kamio H; Noto T; Mano H; Iwamura R; Yoneda K; Odani-Kawabata N; Morishima K; Shams NK
    J Ocul Pharmacol Ther; 2020 Sep; 36(7):529-533. PubMed ID: 32412835
    [No Abstract]   [Full Text] [Related]  

  • 16. Ocular hypotensive effects of anti-glaucoma agents in mice.
    Akaishi T; Odani-Kawabata N; Ishida N; Nakamura M
    J Ocul Pharmacol Ther; 2009 Oct; 25(5):401-8. PubMed ID: 19857101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys.
    Gabelt BT; Hennes EA; Bendel MA; Constant CE; Okka M; Kaufman PL
    J Ocul Pharmacol Ther; 2009 Feb; 25(1):1-8. PubMed ID: 19232013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newly or switching effect of a selective EP2 agonist on intraocular pressure in Japanese patients with open-angle glaucoma.
    Ueda K; Sakata R; Fujishiro T; Honjo M; Shirato S; Aihara M
    Jpn J Ophthalmol; 2022 Sep; 66(5):434-439. PubMed ID: 35906503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan.
    Nakazawa T; Takahashi K; Kuwayama Y; Nomura A; Shimada F
    Adv Ther; 2022 Mar; 39(3):1359-1374. PubMed ID: 35072890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of early medication persistence with omidenepag isopropyl, a topical selective prostaglandin EP2 agonist, in patients with glaucoma: a retrospective two-institute study.
    Nakakura S; Kanamori A; Fukuma Y; Wakabayashi S; Nagata Y; Adachi M
    BMJ Open; 2021 Jan; 11(1):e040301. PubMed ID: 33514572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.